Please assess the completion status of the following clinical trial:

Trial Title: Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 years or above~* Patients scheduled for elective total knee replacement~Exclusion Criteria:~* Active bleeding or high risk of bleeding contraindicating treatment with Low Molecular Weight Heparin (LMWH)~* Contraindication listed in the labeling or conditions precluding subject treatment with enoxaparin or requiring dose adjustment (e.g. severe renal impairment, please refer to the local label of enoxaparin in your country)~* Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939)) (Type: EXPERIMENTAL): Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
- Enoxaparin 30 mg twice a day (bid) (Type: ACTIVE_COMPARATOR): Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).